COVID‐19 vaccination in patients with rheumatic diseases: Vaccination rates, patient perspectives, and side effects
Authors:
Open Access
- 31 January 2022
- journal article
- research article
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 10 (3) , e589
Abstract
Introduction: To investigate the vaccination rate, reported side effects, and patient concerns for COVID‐19 vaccination in patients with rheumatic diseases.Methods: A multicentre cross‐sectional study from rheumatology clinics in two major hospitals in Hong Kong was conducted between June 3, 2021 and October 8, 2021. Patient interviews for demographics, clinical characteristics, vaccination status, reported side effects, and factors influencing decisions about vaccination were supplemented with structured questionnaires.Results: Out of 1367 patients, 413 (30.2%) had received COVID‐19 vaccination. Side effects were reported in 335 (81.1%) of patients, of which the most common were injection site pain or swelling (66.3%), fatigue (57.1%), fever (19.9%), and headache (19.6%). Multivariate logistic regression models showed that males (odds ratio [OR] = 1.80; p < .001), higher education level (OR = 1.64; p < .001) and healthcare professionals (OR = 4.5; p < .001) were significantly more likely to have received the vaccine. In contrast, patients with hypertension (OR = 0.73; p = .04), systemic lupus erythematous (OR = 0.53; p < .001), stroke (OR = 0.29; p = .01), steroid therapy (OR = 0.59; p = .01), and leflunomide therapy (OR = 0.45; p = .05) were significantly less likely to be vaccinated. Younger age (age, OR = 0.96; p = .003) and messenger RNA (mRNA) vaccines (OR = 4.79; p < .001) were associated with more side effects. There was no difference in risk of side effects between specific rheumatic diseases or drug therapies.Conclusion: COVID‐19 vaccination is associated with no increased risk of side effects in any particular disease or drug therapy, therefore vaccination should be encouraged in patients with rheumatic disease. In addition, younger age is associated minimally, while mRNA vaccine is associated with increased side effects.Keywords
This publication has 24 references indexed in Scilit:
- Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask WearersAnnals of Internal Medicine, 2021
- Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysisAnnals of the Rheumatic Diseases, 2021
- Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong KongVaccine, 2021
- Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional surveyJournal of Hospital Infection, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Rheumatic disease and COVID-19: epidemiology and outcomesNature Reviews Rheumatology, 2020
- Vaccine hesitancy: the next challenge in the fight against COVID-19European Journal of Epidemiology, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseasesVaccine, 2018
- Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor ActivityJournal of Immunotherapy, 2011